Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date.

Published

Journal Article (Review)

Although an increasing number of clinical trials have been developed for cognition in Down syndrome, there has been limited success to date in identifying effective interventions. This review describes the progression from pre-clinical studies with mouse models to human clinical trials research using pharmacological interventions to improve cognition and adaptive functioning in Down syndrome. We also provide considerations for investigators when conducting human clinical trials and describe strategies for the pharmaceutical industry to advance the field in drug discovery for Down syndrome. Future research focusing on earlier pharmaceutical interventions, development of appropriate outcome measures, and greater collaboration between industry, academia, advocacy, and regulatory groups will be important for addressing limitations from prior studies and developing potential effective interventions for cognition in Down syndrome.

Full Text

Duke Authors

Cited Authors

  • Hart, SJ; Visootsak, J; Tamburri, P; Phuong, P; Baumer, N; Hernandez, M-C; Skotko, BG; Ochoa-Lubinoff, C; Liogier D'Ardhuy, X; Kishnani, PS; Spiridigliozzi, GA

Published Date

  • November 2017

Published In

Volume / Issue

  • 173 / 11

Start / End Page

  • 3029 - 3041

PubMed ID

  • 28884975

Pubmed Central ID

  • 28884975

Electronic International Standard Serial Number (EISSN)

  • 1552-4833

Digital Object Identifier (DOI)

  • 10.1002/ajmg.a.38465

Language

  • eng

Conference Location

  • United States